For the treatment of patients with metastatic breast cancer by humanized anti-human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. "A guideline for HER2 testing" and "HER2 atlas" produced by the "Pathological committee for optimal use of trastuzumab" are introduced in this report. Appropriate evaluations of biological markers are essential for targeting therapy.
- Breast cancer
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Pharmacology (medical)